A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

This study is testing a new gene therapy for people with multiple myeloma — a type of blood cancer — whose cancer has come back or stopped responding to multiple prior treatments. **You may be eligible if...** - You have relapsed or refractory multiple myeloma with measurable disease - You have received at least 3 prior lines of treatment, including a proteasome inhibitor (e.g., bortezomib), an immunomodulatory drug (e.g., lenalidomide), and a CD38-targeting antibody (e.g., daratumumab) - You are in good overall health (ECOG performance status 0–1) - Your blood counts and organ function meet the study requirements **You may NOT be eligible if...** - Your myeloma has spread to the central nervous system (brain/spinal cord) - You have plasma cell leukemia, Waldenström's macroglobulinemia, POEMS syndrome, or primary light chain amyloidosis - You have other medical conditions that would make this therapy unsafe Talk to your doctor to see if this trial is right for you.